Gamco Investors INC. ET AL lowered its stake in CVS Health Corp (NYSE:CVS) by 27.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 765,246 shares of the pharmacy operator’s stock after selling 283,990 shares during the period. Gamco Investors INC. ET AL owned 0.08% of CVS Health worth $55,480,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Pathstone Family Office LLC lifted its holdings in shares of CVS Health by 341.0% during the second quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock worth $2,353,000 after purchasing an additional 982 shares during the period. Wealthcare Advisory Partners LLC raised its stake in CVS Health by 330.3% during the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 991 shares during the last quarter. Fieldpoint Private Securities LLC raised its stake in CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 1,000 shares during the last quarter. Arcadia Investment Management Corp MI raised its stake in CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after buying an additional 726 shares during the last quarter. Finally, MPS Loria Financial Planners LLC bought a new position in CVS Health during the second quarter worth $119,000. Hedge funds and other institutional investors own 83.96% of the company’s stock.
Shares of CVS Health stock opened at $65.65 on Monday. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59. The company has a market cap of $66,604.02, a PE ratio of 10.15, a PEG ratio of 1.09 and a beta of 1.03. CVS Health Corp has a 52-week low of $65.65 and a 52-week high of $84.00.
CVS Health (NYSE:CVS) last released its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The business had revenue of $48.39 billion for the quarter, compared to analysts’ expectations of $47.54 billion. During the same period in the previous year, the company earned $1.71 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. research analysts anticipate that CVS Health Corp will post 6.37 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, May 3rd. Investors of record on Monday, April 23rd will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 3.05%. The ex-dividend date is Friday, April 20th. CVS Health’s dividend payout ratio (DPR) is presently 30.91%.
A number of brokerages recently weighed in on CVS. Needham & Company LLC raised shares of CVS Health from a “buy” rating to a “strong-buy” rating and lifted their target price for the stock from $88.00 to $100.00 in a research note on Tuesday, January 30th. Mizuho set a $95.00 price target on shares of CVS Health and gave the company a “buy” rating in a research note on Wednesday, January 24th. Cowen reaffirmed an “outperform” rating and issued a $99.00 price target (up from $81.00) on shares of CVS Health in a research note on Thursday, January 18th. Vetr downgraded shares of CVS Health from a “hold” rating to a “sell” rating and set a $76.66 price target for the company. in a research note on Tuesday, January 16th. Finally, ValuEngine downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $87.03.
In related news, EVP Helena Foulkes sold 19,965 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the transaction, the executive vice president now directly owns 65,072 shares in the company, valued at $4,622,714.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the transaction, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The disclosure for this sale can be found here. 0.61% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://ledgergazette.com/2018/03/19/cvs-health-corp-cvs-shares-sold-by-gamco-investors-inc-et-al.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.